Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | TSPO | P30536 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 3/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17150901 | 0.86 | KMT2A (0.45) | ADORA3ADORA1ADORA2A | |
| SCHEMBL17144141 | 0.82 | CDK1 (0.57) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL16714635 | 0.80 | ADORA2A (0.49) | ADORA3ADORA1ADORA2AADRA2AHTR2C | |
| SCHEMBL786455 | 0.78 | ADORA2A (0.49) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL30332114 | 0.78 | ADORA2A (0.49) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL786016 | 0.76 | ADORA2A (0.50) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL30584024 | 0.76 | ADORA2A (0.50) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL17144451 | 0.75 | LMNA (0.41) | ADORA3CHKA | |
| SCHEMBL21176096 | 0.75 | CHKA (0.63) | CHKA | |
| SCHEMBL21176097 | 0.75 | CHKA (0.63) | CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015151006-A1 | SUBSTITUTED PURINE COMPOUNDS AS BTK INHIBITORS | LUPIN LIMITED (IN) | 2015-10-08 | — | — | WO | disclosed |